Absorption and pharmacokinetics of green tea catechins in beagles

The present study evaluates for the first time in dogs, the kinetics of green tea catechins and their metabolic forms in plasma and urine. Ten beagles were administered 173 mg (12·35 mg/kg body weight) of catechins as a green tea extract, in capsules. Blood samples were collected during 24 h after intake and urine samples were collected during the following periods of time: 0-2, 2-6, 6-8 and 8-24 h. Two catechins with a galloyl moiety and three conjugated metabolites were detected in plasma. Most of the detected forms in plasma reached their maximum plasma concentration (Cmax) at around 1 h. Median Cmax for (2)-epigallocatechin-3-gallate (EGCG), (2)-epicatechin-3-gallate (ECG), (2)-epigallocatechin glucuronide (EGCglucuronide), (2)-epicatechin glucuronide (EC-glucuronide), (2)-epicatechin sulphate (EC sulphate) were 0·3 (range 0·1-1·9), 0·1 (range 0-0·4), 0·8 (range 0·2-3·9), 0·2 (range 0·1 1·7) and 1 (range 0·3-3·4) mmol/l, respectively. The areas under the plasma concentration v. time curves (AUC0!24) were 427 (range 102-1185) mmol/l £ min for EGC-glucuronide, 112 (range 53-919) mmol/l £ min for EC-sulphate, 71 (range 26-306) mmol/l £ min for EGCG, 40 (range 12-258) mmol/l £ min for EC-glucuronide and 14 (range 0·1-124) mmol/l £ min for ECG. The values of mean residence time (MRT0!24) were 5 (range 2-16), 2 (range 1-11), 10 (range 2-13), 3 (range 2-16) and 2·4 (range 1-18) h for EGCG, ECG, EGC-glucuronide, EC-glucuronide and EC sulphate, respectively. In urine, catechins were present as conjugated forms, suggesting bile excretion of EGCG and ECG. Green tea catechins are absorbed following an oral administration and EGC-glucuronide is the metabolic form that remains in the organism for a longer period of time, suggesting that this compound could suffer an enterohepatic cycle.

Comment bien identifier les adolescents présentant une consommation alcoolique excessive?

Le mésusage d'alcool par les jeunes est une préoccupation majeure de santé publique. Les données des enquêtes Health Behavior in School-Children (HBSC), concernant la Suisse, indiquent que la prévalence de jeunes de 15 ans indiquant ayant eu au moins deux alcoolisations au cours de leur vie est restée relativement stable parmi les garçons, entre 1998 (28%) et 2010 (27%), tandis qu'elle a légèrement augmenté chez les filles (de 16% à 20% pour les mêmes années). Les données d'une étude du réseau Sentinella auprès de jeunes de 10-24 ans (moyenne 17,7) indiquent que 44% d'entre eux n'ont jamais consommé d'alcool, 49% quelques fois, et 7% régulièrement. La même étude révèle que près de 70% de ces jeunes ne rapportent aucun épisode de binge drinking, 24% entre 1 et 10 épisodes, et 7% plus que 10 épisodes au cours de l'année écoulée. Parmi ceux indiquant au moins un épisode de binge drinking, la grande majorité (61.5%) ont entre 20 et 24 ans.

Monimuotoisuus organisaatiossa - monimuotoisuustutkimuksen pääpiirteitä ja kehityslinjoja

Abstract: Workforce diversity in organizations - the main features and developments of diversity research

EU-säätelijä lääketeollisuudessa: ylikansallinen sääntely ja tutkimus- ja kehitystyö

Lectio praecursoria Tampereen yliopisto, johtamistieteiden laitos

Ikäjohtaminen hoitotyössä

Abstract: Age management in nursing care

Kilpailu, yhteistyö, työnjako

Summary: Competition is high on the agenda of the economics.

EU:n uusi varainhoitoasetus yleisen talousarvion joustavuuden kannalta

Artikkelin ensimmäinen osa on julkaistu Hallinnon tutkimuksessa 23 (2004): 3, 14-17.

Tasapainoitettu tuloskortti (BSC) hoitotyön johtamisessa - mittarit ja niiden yhteys strategioihin

Abstract

Neljännen sukupolven evaluaation jälkeinen arvointitutkimus?

Abstract

Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.

BACKGROUND: Psychotropic drugs can induce substantial weight gain, particularly during the first 6 months of treatment. The authors aimed to determine the potential predictive power of an early weight gain after the introduction of weight gain-inducing psychotropic drugs on long-term weight gain. METHOD: Data were obtained from a 1-year longitudinal study ongoing since 2007 including 351 psychiatric (ICD-10) patients, with metabolic parameters monitored (baseline and/or 1, 3, 6, 9, 12 months) and with compliance ascertained. International Diabetes Federation and World Health Organization definitions were used to define metabolic syndrome and obesity, respectively. RESULTS: Prevalences of metabolic syndrome and obesity were 22% and 17%, respectively, at baseline and 32% and 24% after 1 year. Receiver operating characteristic analyses indicated that an early weight gain > 5% after a period of 1 month is the best predictor for important long-term weight gain (≥ 15% after 3 months: sensitivity, 67%; specificity, 88%; ≥ 20% after 12 months: sensitivity, 47%; specificity, 89%). This analysis identified most patients (97% for 3 months, 93% for 12 months) who had weight gain ≤ 5% after 1 month as continuing to have a moderate weight gain after 3 and 12 months. Its predictive power was confirmed by fitting a longitudinal multivariate model (difference between groups in 1 year of 6.4% weight increase as compared to baseline, P = .0001). CONCLUSION: Following prescription of weight gain-inducing psychotropic drugs, a 5% threshold for weight gain after 1 month should raise clinician concerns about weight-controlling strategies.